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Abstract

Determining the binding affinity and potency in vitro is one of the significant steps
that can give a clue for a new candidate drug during the drug discovery process.
Thermofluor is a method used in measuring binding affinity (Kd) of protein-ligands
interaction through determining the change in thermal denaturation temperature of
protein using real time PCR (RT-PCR). Kinetic analysis assay is used to screen a
library of compounds to calculate their potencies (IC50) and inhibition constants (Ki)
and it can be performed by spectrophotometer technique. In this study, we used
bovine carbonic anhydrase II (BCA II) enzyme, and four of its inhibitors as a model
to compare drug affinities, which were determined either by Fluorescence Thermal
Shift Assay (FTSA) using Sypro Orange dye or kinetic assay using 4-Nitrophenyl
acetate as a substrate to measure the nonphysiologically esterase activity of CA. The
inhibitors studied were Methazolamide, Brinzolamide, Dorzolamide HCl and
Mafenide HCl. The Kd values were determined to be 5.4±0.085 µM, 1.2±0.44 µM,
2.08±0.63 µM, and IC50 values were 0.148±0.024 µM 0.129±0.015 µM 0.092±0.01
µM 1.715±0.16 µM whereas the Ki values were 4±0.55 nM, 3.5±0.5 nM, 2.5±0.5 nM
and 46.5±6.5 nM for Methazolamide, Brinzolamide, Dorzolamide HCl and Mafenide
HCl, respectively. The potencies (IC50) of the inhibitors were10-50 fold lower than
that of the Kd values. In addition, Kd values were higher compared to Ki values.
Therefore, kinetic analysis is a more sensitive technique and requires a lower amount
of the enzyme to measure drug affinity than FTSA.
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Background: Literature Review

Drug discovery
The drug discovery process takes about 12-15 years, and more than 1 billion
dollars to come up with any new candidate drug (Fig. 1). It may take many years to
build up a body of supporting evidence before selecting a target for a costly drug
discovery program. Many challenges are present in drug discovery and
pharmaceutical industry, such as target identification, hit to lead optimization and
evaluation of drug candidates (Hughes, Rees, Kalindjian, & Philpott, 2011)..
The hit to lead to process is a valuable technique for distinguishing drug
candidates. Determining the binding affinity and potency in vitro, is one of the hit to
lead optimization steps that can give a clue for the candidate drug (Wang, Dong, &
Sheng, 2019). Creating of methods for rapid screening of inhibitors of specific
enzyme from compound library is one of the main challenges in drug discovery,
especially for new targets where the goal is to study and recognize their potential
inhibitors (Lo et al., 2004).
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Figure 1: Drug discovery process. FDA, Food and Drug Administration; IND,
Investigational New Drug; NDA, New Drug Application (Hughes et al., 2011).

Universal and valid drug discovery assay technique are desired in order to get
ahead with the latest developments in combinatorial chemistry and genomics-based
target production (Pantoliano et al., 2001).Enzymatic assays (e.g. Fluorescence or
absorbance spectroscopy) are commonly used in measuring the potencies of
compounds in laboratories. While binding assay such as Fluorescence Thermal shift
Assay (FTSA) is used to measure the compound affinity. Many compounds that are
assumed to be potential drugs in treating human diseases, are firstly known through
studying their binding properties like affinity and potency (FDA, 2003).

Enzymatic assay (kinetic analysis):
Enzymatic assays play critical roles in determining the reaction rate, binding
affinity, catalytic constant, and inhibition rate as well as screening library of
compounds. (FDA, 2003).
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One of the major assays is used to estimate Vmax (the maximum velocity of
the reaction) and KM (Michaelis-Menten constant), which is the substrate
concentration at half of V max (Eq. 1) (Choi, Rempala, & Kim, 2017). Where the rate
of the reaction is measured in time course by monitoring the absorbance of the
product release or the substrate consumption over period of time ((Boeckx, Hertog,
Geeraerd, & Nicolai, 2017)..

𝝊=

𝑽𝒎𝒂𝒙[𝑺]

Eq. 1

𝑲𝒎+[𝑺]

Where [S] is the substrate constant; Vmax is the maximal velocity and Km is the
Michaelis constant which is the substrate concentration of Vmax/2
IC50 Assay:
Dose response relationship is displayed by fitting the response against the log
of the inhibitor concentration through the application of the equation of FourParameter Logistic Function (Eq. 2), (Krohn & Link, 2003).
𝑻𝒐𝒑−𝑩𝒐𝒕𝒕𝒐𝒎

𝒚 = 𝑩𝒐𝒕𝒕𝒐𝒎 + 𝟏+𝟏𝟎 𝒍𝒐𝒈𝑰𝑪𝟓𝟎−𝒍𝒐𝒈𝒙 ∗𝑯𝒊𝒍𝒍𝑺𝒍𝒐𝒑𝒆

Eq. 2

Where y is: response, x: log of inhibitor concentration, Top and Bottom: plateaus in
same unit as y, same log unit as x, Hillslope: slop factor or hill slop (unitless).
High throughput screening assays are mainly used to examine enzyme activity
and inhibitor efficacy. A total inhibitor concentration that decreases enzyme activity
by 50% (IC50) is the most used pharmacokinetic measure of a drug's efficacy and
potency. It is a quantitative measure that indicates the concentration of a drug or
substance that is required to inhibit a specific biological activity by a half (Aykul &
Martinez-Hackert, 2016).
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Inhibition constant Ki:
Inhibition constant (Ki) is a guide of how potent an inhibitor is, and it is the
concentration of the inhibitor desired to produce half maximum inhibition. For
competitive inhibitors It can be calculated by Cheng-Prusoff equation (Eq. 3)
(Lazareno & Birdsall, 1993).

𝐾𝑖 =

𝐼𝐶50
1+ 𝑆 /𝐾𝑚

Eq.3

Binding assays:

Binding affinity is the strength of the binding interaction between protein and
its ligands (like inhibitors or activators). It is generally estimated by the binding
affinity constant also known as equilibrium dissociation constant (Kd). The smaller
the Kd value, the greater the binding affinity of the ligand for its target(Pollard, 2010)
There are multiple methods available for detection of dissociation constant
(Kd)value of protein-ligand interactions. Such as, Surface Plasmon Resonance (SPR)
which is an approach that requires transfer of electromagnetic energy to electrons in a
thin layer of metal (e.g. Gold) in contact with a solution.
Fluorescence Polarization (FP)is another method used; it measures the change
in the rate of the rotation of a fluorophore which can be detected by alteration in
polarization. This method depends on the binding of a fluorescent ligand to a protein
which causes the ligand to rotate more slowly. Isothermal Titration Calorimetry
(ITC): This method quantifies the heat produced from a chemical reaction in solution.
Because almost all enzyme-ligand reactions release or consume heat, and no
fluorescent labels of the enzyme or ligand are required. ITC is the only known method
4

capable to immediately measure the enthalpy, ΔH, of a ligand binding to a
protein(Mittermaier & Meneses, 2013).
Thermofluor also known as Thermal shift assay (TSA) or Differential
Scanning Fluorimetry (DSF), measures the change in thermal denaturation
temperature of a protein under different conditions (e.g., pH, salts, additives, drugs or
mutations).And this method requires only RT-PCR machine, data can easily be
analyzed as many protocols are available to quantify the data from TSA to rapidly
demonstrate Kd values and predict the binding affinity of protein-ligand interaction
(Mittermaier & Meneses, 2013).
FTSA (Fluorescence Thermal Shift Assay) monitors thermal unfolding of
proteins in the presence of a ﬂuorescent dye which is highly ﬂuorescent in non-polar
environment, such as the hydrophobic sites on unfolded proteins, compared to
aqueous solution where the ﬂuorescence is quenched (Fig. 2). Usually, TSA can be
applied for variety of enzymes where it is run by a real-time PCR instrument (Niesen,
Berglund, & Vedadi, 2007).

This assay is used for detection of protein-ligand interactions. After the ligand
binds to the folded protein, it will stabilize it. As a result of that, it will increase the
melting temperature (Tm), which is needed to unfold the protein. In consequence, this
will result in shifts in unfolding curves and Tm to give (∆Tm), and analyzing these data
gives the value of the dissociation constant (Kd) which determines the binding affinity
of the ligand (Bai, Roder, Dickson, & Karanicolas, 2019).
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Figure 2: The two-state transition curve. In the first state, the fluorescence intensity
increases upon enzyme unfolding, where the hydrophobic region becomes exposed to
the dye allowing it to bind with the enzyme. After reaching the plateau, in the second
state, the fluorescence intensity begins to decrease as the denatured enzyme-dye
complex starts to aggregate(Bruce, Cardew, Freitag-Pohl, & Pohl, 2019).

Carbonic Anhydrase (CA) Overview:
Carbonic Anhydrase is an enzyme which requires zinc ion to function as a
Lewis acid in the reaction mechanism at the active site, where it can be coordinated to
three histidine and a hydroxide ion to catalyze the reversible hydration of carbon
dioxide (CO2) and dehydration of bicarbonate ion (HCO3-) (Eq. 4) (Iqbal, Nisar-UrRahman, & Iqbal, 2014; Iyer, Barrese, Parakh, Parker, & Tripp, 2006).
CO2 + H2O⇌HCO3- + H+

(Eq. 4)
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CAs are present in plant and animal tissues. There are several classes of
CAs; α, β, γ, δ and δ. α- class is found in bacteria and mammals, and about 16
different mammalian isozymes such as CA I, CA II, CA III, CA IV …etc. were
described (Taslimi et al., 2016). CAs I and II are abundantly found in red blood cells
of mammals where CA II is one of the most known isozymes in α- class that was
discovered in 1933 by Meldrum and Rougton (Meldrum & Roughton, 1933). Bovine
carbonic anhydrase II (BCA II) is similar to the human one(Iqbal et al., 2014) and it is
a cytosolic, single-chain, approximately 30 KDa enzyme. In addition, CAs are found
in mammals, and can be divided in four subgroups according to their localization;
cytosolic, mitochondrial, membrane bound with extracellular domains or secreted
(Krishnamurthy et al., 2008a).
Carbonic anhydrase enzyme is involved in different physiological processes,
such as pH homeostasis, calcification, respiration, vision, gas exchange and bone
resorption (Krishnamurthy et al., 2008a). These functions make it a target for many
drugs that function as CA inhibitors. CA anhydrase inhibitors are used in many
conditions such as; glaucoma, cancer, epilepsy, obesity, heart failure and intercranial
hypertension. Examples include, sulfonamides which are the most common inhibitors
class of CA (Iqbal et al., 2014). Additionally, methazolamide and brinzolamide
which help in reduction of elevated intraocular pressure in patients with open-angle
glaucoma or ocular hypertension, dorzolamide is used in the treatment of acute or
chronic vascular hypertension and mafenide used as antibacterial agent (Brunton,
L.B., Lazo, J.S., & Parker, 2005).
CA is an excellent model for studying enzyme kinetics for small
molecule ligands due to several reasons. These include the fact that it does not contain
disulfide bonds, it is monomeric, stable, it can be easily purified, it has known amino
7

acid sequences, and the mechanism of its catalytic activity is known. Additionally ,
the mechanism of inhibition of it is well understood and it is easy to evaluate the
binding of ligands by different high throughput assays (Krishnamurthy et al., 2008a).
The assays that study the CA activity can be generally subdivided into
main groups. One method includes CO2 consumption detection, where carbonic
dioxide and carbonate act as substrates for estimation of CA activity. Also, stoppedflow assay which estimates the CA activity by monitoring the pH changes of
dehydration of HCO3- to CO2 or the reverse reaction (Krishnamurthy et al., 2008a). In
1965, Pocker and Stone established another type of assay to measure the CA activity,
and a spectrophotometric technique for verifying the esterase activity of CA by
catalyzing the non-phycological hydrolysis of esters like hydrolysis of 4-Nitrophenyl
acetate (4-NPA). The product (nitrophenolate) ionizes to give yellow nitrophenolate
anion which can be detected at 400 nm by using UV-spectrophotometer (y. pocker,
1965).

Can we use FTSA to study the binding affinity?

Generally, Thermofluor (FTSA) is easy, fast, and inexpensive. It does not
require creating new assays with each new target and can be used also for any
unknown compound method to measure the binding affinity of the compounds other
than the known enzymatic assays, these advantages could be an improvement of drug
discovery field (Matulis, Kranz, Salemme, & Todd, 2005).
Recently, FTSA method is used in studying the binding affinity Kd of the hit
compounds as qualitative measurement, and there are many approaches and protocols
8

applied in order to concede this method for quantitative measurement. Therefore,
enzymatic assay has been conducted for a variety of enzymes with different ligands to
determine IC50 values and compared them with the binding affinity constant (Kd)
values that is obtained from thermal shift assay.
Lo et al., (2004) compared the binding affinities measured by FTSA and ITC
with the IC50 values, which were measured by enzymatic assay, using β-site amyloid
precursor protein-cleaving enzyme 1 (BACE1). They concluded that Kd values from
FTSA are correlated to the Kds that were obtained from ITC and IC50 from enzymatic
assay. In addition, they suggested that candidate hits can be determined based on ∆Tm
values, if FTSA can be run at appropriate compound concentrations in connection to
their dissociation constants.
Bai et al., (2019) proposed and established new approach for analyzing FTSA
data using experimental data for maltose binding protein (MBP) and maltose, and for
two carbonic anhydrase isoforms with four of their inhibitors. Enzymatic assay was
applied to determine the inhibition constant (Ki) to obtain an independent measure of
the interaction between the enzyme and each of the inhibitors. They concluded that
there is a corelation between the binding constant and the inhibition constant,
especially for potency range between uM to mM range.
Smirnovienė, Smirnovas, & Matulis, (2017) studied the importance of
inhibition and binding assays using carbonic anhydrase by applying enzymatic
stopped-flow CO2 assay and FTSA, respectively. Kd of picomolar was successfully
measured by FTSA, which is promising in drug discovery world. As a result, a
correlation between IC50 and Kd is observed. Moreover, they suggested that the
combination between the two methods can give a higher quality and precise data.
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In this study, carbonic anhydrase enzyme was used as a model with four of its
known competitive inhibitors (methazolamide, brinzolamide, dorzolamide HCl and
mafenide HCL) to perform kinetic assays and FTSA using uncomplicated and
straightforward protocol(Iyer et al., 2006; Laubach, A. E., Wang, E., & Anderson,
2015). Then comparison was made between the potency (IC50), inhibition constant
(Ki) and binding affinity (Kd) to demonstrate if FTSA is suitable and practical for
screening of inhibitors and identifying hit compound. In addition, optimization of the
FTSA technique was done to build up an effective and easily use method to determine
drug affinity.

Materials and Methods

Carbonic Anhydrase concentration determination:
Stock solutions of each of methazolamide(Sigma-Aldrich, St. Louis, MO),
brinzolamide (Selleck Chemicals, Houston, TX) and mafenide HCl (Selleck
Chemicals, Houston, TX) were prepared in 100% DMSO, and Dorzolamide HCl
(Selleck Chemicals, Houston, TX) was prepared in distilled water to make 10 mM
solution. 2 mg/ml of bovine CAII (Sigma-Aldrich, St. Louis, MO) was prepared using
buﬀ er (Tris-HCl, pH 8.2). 20X solution of SYPRO Orange dye (Invitrogen™
Molecular Probes™, 5,000X Concentrate in DMSO) were prepared in (Tris-HCl, pH
8.2).
To monitor the enzyme unfolding a total of 20 µL of mixture contains 2 µl of
SYPRO Orange dye (2X final concentration), 2 µl of Bovine CAII (0.0008-0.1)
mg/ml, and 16 µl of Tris-HCl buffer were mixed on 96-well PCR plate. A18 µL of
10

buffer and 2 µL of Sypro Orange dye was used as control. Then the assay plate
covered with a sheet of optically clear adhesive. Main measurements were carried out
in duplicate. Then fluorescence was measured from 25℃ for 2 minutes then 1℃/min to
95℃ (excitation, 450-490 nm; detection, 560-580 nm.) Then, FTSAs were performed
on a StepOnePlus Real-Time PCR System (ThermoFisher, Waltham, Massachusetts,
USA.). Then data was fitted using Excel 2013 (Microsoft, Redmond, WA) program.
Initially, Sypro Orange dye was compared with GloMelt™ dye (Sybr Green
dye manufactured by Biotium Inc. Fremont, CA). A total of 20 µl mixture was used in
the assay with different concentrations of the enzyme (0.0008-0.1) mg/ml, with either
2 µl of 2X of Sypro Orange or 2X of Sybr Green, and 16 µl Buffer. 2 µl of dye and 18
µl of buffer were added together as a control. Then fluorescence was measured from
25℃ for 2 minutes then 1℃/min to 95℃ (excitation, 450-490 nm; detection, 560-580
nm.) by RT-PCR.
The signal of Sypro Orange was found to be stronger (Fig. 3). A possible
explanation for this finding is the difference in the sensitivity of RT-PCR machine. In
addition, Sypro Orange has many advantages compare to Sybr Green dye; it is
inexpensive, easy to prepare and can be stored at room temperature.
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Figure 3: Comparison of fluorescence signal with Sypro Orange dye and Sybr Green
dye at 0.1 mg/ml BCA II concentration.

Determination of kd of the inhibitors

FTSA was run using a total of 20 µl mixture, which contained 2 µl of Sypro
Orange dye (2X final concentration), 12 µl of Tris-HCl buffer, 2 µl of BCA II (0.1
mg/ml in assay) and 4 µL of different concentrations (0.23 – 100 µM) of either
methazolamide, brinzolamide or dorzolamide HCl, and (0.46-200 µM) of Mafenide
HCL were mixed in 96-well plate. As a positive control, 2 µl of Carbonic anhydrase,
2 µL of the dye and 16 µl of buffer were added together. 1% DMSO was used as a
negative control. Then the assay plate covered with a sheet of optically clear adhesive
and fluorescence was measured from 25℃ for 2 minutes and then 1℃/min to 95℃
(excitation, 450-490 nm; detection, 560-580 nm.). FTSAs were performed on a
StepOnePlus Real-Time PCR System. Data evaluation and melting temperature Tm
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determination were performed using the GraphPad Prism 8software (GraphPad
software. Inc) and applied Boltzmann Sigmoidal curve equation (Eq.5).

𝒀 = 𝑩𝒐𝒕𝒕𝒐𝒎 +

(𝑻𝒐𝒑−𝑩𝒐𝒕𝒕𝒐𝒎)

Eq. 5

𝑿
)
𝒔𝒍𝒐𝒑

(𝟏+𝐞𝐱𝐩
(𝑻𝒎−

Where Y: fluorescence intensity; X: temperature; Bottom: baseline fluorescence at
low temperature; Top: maximal fluorescence at the top; Slope: the steepness of the
curve; and Tm: melting temperature of the enzyme.
Then the date was analyzed by GraphPad Prism 8 software using the single
site ligand binding equation (Eq. 6) (Vivoli, Novak, Littlechild, & Harmer, 2014):
𝒀 = 𝑩 + ( 𝑻 − 𝑩 ∗ (𝟏 − ((𝑷 − 𝑲𝒅 − 𝑿 +

( 𝑷+𝑿+𝑲𝒅 𝟐 − 𝟒∗𝑷∗𝑿 ))
𝟐∗𝑷

Eq. 6

Where P: protein concentration. Kd: dissociation constant (has the same unit as
P). T: melting temperature at high inhibitor concentration; B: melting
temperatures of no inhibitor concentration.

Enzymatic assay:

Determination of the Enzyme concentration
The catalytic activity of BCA II was monitored by the hydrolysis of the
nonphysiologically ester (4-NPA) (Sigma-Aldrich, St. Louis, MO). The products of
the hydrolysis reaction are acetate and nitrophenolate, which ionizes to give a bright
yellow anion that is detected by measuring its absorbance at 400 nm with a Synergy™
2 spectrophotometer (Biotek instruments Winooski, VT) using 96-well plates.For
initial screens, 200 µl of assay solution containing 10 µl of (0.0008-0.1) mg/ml of
13

BCA II, 10 µl of 4-NPA and 180 µl of Tris-HCl buffer were dispensed into 96-well
plates which were incubated for about 20-30 minutes at room temperature. As a
control 10 µl of the enzyme and 190 µl of the buffer were mixed. Then, the
absorbance was read at 400 nm. The data were plotted on Excel to choose the enzyme
concentration that is suitable to use in the IC50 detection
.
Esterase activity Assay
Calculation of Vmax and Km:
The assay was performed by adding 10 ul of different substrate concentrations
of 4-NPA (0.00195-0.25) mM. In addition, 10 ul of 6 ng/ul BCA (II) and 180 ul of
Tris-HCl buffer were mixed in 96-well plate. Then the absorbance was read at 400 nm
using the spectrophotometer. Michaelis Menten equation (Eq. 1) was applied and the
curve was plotted by GraphPad Prism 8. To find out Km value and Vmax (ƹ = 21,000
M-1cm-1) (Krishnamurthy et al., 2008b).
Calculation of Ki:
To determine the inhibition constants (Ki) values for each one of the inhibitors,
Cheng-Prusoff equation (Eq. 3) was applied.

Calculation of IC50:
The assays were performed by adding10 µl of each methazolamide,
brinzolamide or dorzolamide HCl (0.039-5) µM final concentration or 10 µl of
mafenide HCl (0.078-10 µM), 10 ul of 6 ng/ul of the enzyme, 10 µl of 4-NPA
substrate (0.25 nM final concentration) and 170 µl of the buffer. Less than 1% DMSO
14

was used as a control. The normalized data were then fit to the 4-parameter nonlinear
sigmoidal dose-response model using GraphPad Prism version 8 software to obtain
the IC50 and Hill slope (Eq. 2) (Iyer et al., 2006).

Results
The thermal unfolding of different concentrations of BCA II was monitored by
RT-PCR thermocycler which generated curves that showed a two-state transition (Fig.
2). In the first state, the fluorescence intensity increases upon enzyme unfolding,
where the hydrophobic region becomes exposed to the SYPRO Orange dye allowing
it to bind with the enzyme. After reaching the plateau, in the second state, the
fluorescence intensity begins to decrease as the denatured enzyme-dye complex starts
to aggregate. Comparing the fluorescence intensity of different concentrations of BCA
II showed that the 3.33 µM concentration of the enzyme gives the highest read of the
fluorescence intensity (Fig. 4), so it was chosen to be used in the FTSA experiment to
measure the binding affinity (Kd) of the inhibitors. Determination of protein stability
and its melting temperature were obtained by FTSA, followed by data analysis using
GraphPad Prism 8®, the average time was about 3 hours.
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Figure 4: Thermal unfolding of different concentrations of BCA II (3.33 µM, 1.67
µM, 0.83 µM and 0.42 µM) monitored by 2X SYPRO Orange each in triplicate.
Normalization was done by using Boltzmann equation.

The Melting temperatures Tm (the midpoint of the first state of fluorescence
transition) were calculated using (Eq.3). As the inhibitor binds at the hydrophobic
region of the unfolding enzyme, the melting temperature Tm increases. The calculated
Tm of the enzyme was higher in the presence of the inhibitor and positively correlated
to the inhibitor concentration (Figures 5A, 6A, and 7A) show the shifts in melting
temperature curves of methazolamide, brinzolamide and dorzolamide HCl,
respectively.
The stability of the enzyme increases as the inhibitor concentration is
increased. Binding affinity constants (Kds) were calculated using (Eq. 4) for the four
inhibitors and they were 5.4±0.085 µM, 1.2±0.44 µM, 2.08±0.63 µM for
methazolamide, brinzolamide and dorzolamide, respectively. (Figures 5B, 6B and 7B)
show ∆Tm values which are significant and increased with the inhibitor concentration.
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∆Tm is large for the higher affinity inhibitor and decreased when the affinity
decreases. Kd value of mafenide HCl was hard to detect and it was difficult to observe
the Tm shifts where ∆Tm was less than 2 ℃. This could be due to the low solubility of
mafenide HCl at high concentration (Figure 8).
.
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Figure 5 (A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Methazolamide. Data
fit to Boltzmann equation gave midpoint Tm of 71˚C, 70˚C, 69.5˚C, 68.5˚C and 65˚C,
respectively, (R2 ≥ 0.9). (B) ∆Tm s are ranging between (0 – 6) ˚C. n = 3 independent
experiments.
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Figure 6(A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Brinzolamide. Data fit
to Boltzmann equation gave midpoint Tm of 77˚C, 76.7˚C, 75.6˚C, 74˚C and 64˚C,
respectively, (R2 ≥ 0.9). (B) ∆Tm s are ranging between (0 – 13.45) ˚C. n = 3
independent experiments.
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Figure 7: (A)Thermal shift curves of unfolding transition of 3.33 µM CA II in the
presence of 100 µM, 44.5 µM, 19.8 µM, 8.8 µM and 0 µM of Dorzolamide HCl. Data
fit to Boltzmann equation gave midpoint Tm of 76˚C, 74˚C, 73˚C, 72˚C and 64˚C,
respectively, (R2 ≥ 0.9). (B) ∆Tm s are ranging between (0 – 12.6) ˚C. n = 3
independent experiments.
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Figure 8: Thermal shift curves of unfolding transition of 3.33 µM BCA II in the
presence of 200 µM, 133 µM, 12 µM and 0 µM of Mafenide HCl. Data fit to
Boltzmann equation gave midpoint Tm of 66.8˚C, 66.7˚C, 66˚C and 65˚C,
respectively, (R2 ≥ 0.9). n = 3 independent experiments.
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Vmax and Km results:

The Km value determined from the initial velocity data was found to be 10 ± 3 µM,
which is an average of three trials and the error is the standard deviation of the three
trials.
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Figure 9: Plot of Michaels-Menten equation. Velocity vs N-NPA concentration was
fitted to the Michaelis-Menten equation (Eqn. 1) to determine the Km value for CA.
The fit for CA II-catalyzed reaction was done using the program GraphPad Prsim ®
version 8. The reactions were performed in triplicate and the average of the three Km
values was 10 ± 3 µM. 4-NPA concentrations (0.00195-0.25) mM and 6 ng/µl of
BCA II.

Ki valuer were calculated using Cheng-Prusoff equation for competitive inhibitors
(methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl), where Km =
10±3 µM and substrate concentration was 0.25 mM(Laubach, A. E., Wang, E., &
Anderson, 2015;Iyer et al., 2006):

𝐾𝑖 =

𝐼𝐶50
1+ 𝑆 /𝐾𝑚
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Ki values were 4±0.55 nM, 3.5±0.5 nM, 2.5±0.5 nM and 46.5±6.5 nM for
methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl, respectively. The
reactions were performed in triplicate n=3.

IC50 results

The results of the half maximal inhibitory concentration (IC50) for
methazolamide, brinzolamide, dorzolamide HCl and mafenide HCl were 0.148±0.024
µM, 0.129±0.015 µM, 0.092±0.01 µM and 1.715±0.16 µM, respectively (Fig.10).
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Figure 10: IC50s values were determined by fitting a dose-response (four parameters)
curve of the inhibition (%) to the data, using the GraphPad Prism program. (R2 ≥ 0.9)
and n = 3 independent experiments.
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The affinity constants (Kd) were about 10-50-fold higher than the potencies
and they were were not close in the magnitudes to those of Ki values (Table 1).
Table 2: Values of Kd, IC50 and Ki
Inhibitor Name

Kd (µM)

IC50 (µM)

Ki (µM)

FTSA

Enzymatic
assay

Enzymatic
assay

Methazolamide

5.4±0.085

0.148±0.024

0.004±0.00055

Brinzolamide

1.2±0.44

0.129±0.015

0.0035±0.0005

Dorzolamide HCl

2.08±0.63

0.092±0.01

0.0025±0.0005

Mafenide HCl

ND

1.715±0.016

0.0465±0.0065

`

Statistical Analysis
For binding assays and enzymatic assays, sample standard deviation for each
condition was calculated using the STDEV.S function in Microsoft Excel and Error
ranges for fitted IC50, Ki and Kd values were defined as 95% confidence intervals.

Discussion
The primary purpose of this study was to examine the ability of
applying FTSA in determination of hit to lead compound in research study by
comparing it with two of the commonly used traditional kinetic analysis
methods by measuring the affinities of four known inhibitors of CA.
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FTSA technique has number of advantages such as: it is easy to use,
inexpensive, the RT-PCR machine used to run the assay is readily available in
most of the laboratories and industries, it doesn’t depend on previous
knowledge of the value of the affinity or potency to modify the conditions of
the reaction, and it can be used as a primary detection method for the
qualitative measurement of the binding affinity of unknown compounds which
is one of the initial steps in the drug discovery process.
The findings of this study for (methazolamide, brinzolamide and
dorzolamide HCl and mafenide HCl) indicate that the Kd values obtained by
FTSA were about 10-50 fold higher than that of the IC50 values that were
obtained from the enzymatic assay. In addition, Kd values were higher
compared to Ki values.
A commonly cited explanation for the difference of these measured
values is that the reaction was conducted under different temperatures. FTSA
uses a high temperature that can probably reach about 77 ℃ Tm compared to
the room temperature (25℃) that is used when running the IC50 assay
(Redhead, Satchell, McCarthy, Pollack, & Unitt, 2017).
The need for a high concentration of the enzyme in this approach to get
the proper fluorescence intensity is required to observe the melting
temperature shifts between different concentrations of the inhibitor. Thereby
making it hard to measure the precise Kd value for a potent drug (Vivoli et al.,
2014).
Some reports in the literature concluded that there is a correlation
between Kd values and IC50 values, which were measured by FTSA and
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traditional enzymatic assay, respectively (Bai et al., 2019; Lo et al., 2004;
Smirnovienė et al., 2017).
The discrepancy between the values of the Kd using the approach of
FTAS which is used in this study as well as the values that were published
using other approaches of FTSA could be due to consideration of the enthalpy
values (∆H) of the reaction in their FTSA approach, which can help measuring
low Kds values. Especially, for high potent inhibitors (Smirnovienė et al.,
2017).
Another finding in this study is that it was difficult to observe the shift
in Tm for mafenide HCl (low potency drug) that could be explained by low
solubility at high concentration. For some ligands such concentration may be
too high due to limited solubility. If the solubility is below the expected Kd,
then the determination is impracticable and hard to obtain. (Cimmperman &
Matulis, 2011) (Matulis et al., 2005).
Limitations of the FTSA include that some ligands may interfere with
the dye or interact covalently with the unfolded enzyme. Enzyme folding
could be reversable and can cause aggregation at higher temperature (Bai et
al., 2019).The binding constant calculated by FTSA is measured at high
temperatures and not in the physiological temperature, and this point should
be taken in consideration when FTSA is compare with enzymatic assay.
However, estimation of lower binding constants Kd is applicable if the Van’t

ᶱ

Hoff enthalpy (∆H ) of binding is known (Matulis et al., 2005). To determine

thermal shift of weakly binding compounds, their concentration should be
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more than the expected Kd. This could be an issue because they may have
limited solubility at high concentration. As a result, it creates a hard
observation of the thermal shift (Cimmperman & Matulis, 2011).
Despite these limitations, FTSA has several advantages like its
simplicity in use for identification of candidate hits, also its general
applicability to large different target proteins. The IC50 values do not
recognize the mechanism of action. Consequently, various unrelated
compounds may exhibit the same activity due to interactions at different sites.
Moreover, FTSA can identify mechanistic information such as stoichiometry
and differentiate covalent and noncovalent interactions. (Matulis et al., 2005)

Conclusion
The findings of this study which compared drug affinities determined by
enzymatic analysis and FTSA showed that the potencies (IC50) of the potent drugs
were 10-50 folds lower than that of the Kd values. In addition, Kd values were higher
compared to Ki values. The higher values of Kd could be explained by the different
temperature conditions used in each assay and the need of high concentration of the
enzyme, which make obtaining Kd lower than a half of this concentration hard. In
addition, it was difficult to distinguish the Tm shifts of Mafenide HCl (µM potent
drug) a possible factor could be its low solubility at high concentration.
Summing up the results, it can be concluded that kinetic analysis is more
sensitive technique, doable and requires lower amount of the enzyme to measure drug
affinity than FTSA. More experiments will be needed to verify whether various
modifications of the FTSA approach (like using different buffers or salts) can predict
more precise measurements of the binding affinity.
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